Afficher la notice abrégée

Chronic polypharmacy at all age: a population-based drug utilization study

dc.rights.licenseopenen_US
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorGUILLOT, Jordan
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorMAUMUS-ROBERT, Sandy
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorPARIENTE, Antoine
IDREF: 13395711X
hal.structure.identifierBordeaux population health [BPH]
dc.contributor.authorBEZIN, Julien
ORCID: 0000-0002-2568-1928
IDREF: 181595710
dc.date.accessioned2021-11-08T13:49:48Z
dc.date.available2021-11-08T13:49:48Z
dc.date.issued2022-04
dc.identifier.issn1472-8206 (Electronic) 0767-3981 (Linking)en_US
dc.identifier.urihttps://oskar-bordeaux.fr/handle/20.500.12278/123776
dc.description.abstractEnPolypharmacy is a growing concern often described only in older people by cumulating all drugs taken. We aimed to describe chronic polypharmacy in France, regardless of age. A cross sectional descriptive study was performed using the 1/97(th) representative sample of the French health insurance nationwide database (EGB). All subjects alive on January 1(st) , 2015 and covered by the French healthcare insurance were included, and their information collected until December 31(st) , 2015 or date of death. Drug exposures were estimated from drug dispensing dates and treatment durations. Chronic uses of drug were defined as drugs used daily for more than 6 months. Chronic polypharmacy corresponded to the exposure to five chronic uses of drug or more. In 2015, information of 584,862 subjects was collected (mean age: 42.2 years). Prevalence of chronic polypharmacy was 5.6% and incidence 1.1%. Prevalence of chronic polypharmacy increased noticeably from 0.2% for subjects aged 18 to 40 years to a maximum of 29.2% for subjects aged 80 to 90 years, and then decreased to 23.6% for subjects aged 90 years and more. Lipid modifying agents were the most frequent drugs involved in chronic polypharmacy (10% of exposure). According to age, the most important differences between the younger and older people were found for cardiovascular drugs (43.5% vs. 45.7% of exposure, respectively) and nervous system drugs (13.7% vs. 11.5% of exposure, respectively). This population-based study showed increasing of chronic polypharmacy and evolution of chronic drug patterns with age.
dc.language.isoENen_US
dc.subject.enAged
dc.subject.enDrug utilization
dc.subject.enMiddle-aged
dc.subject.enObservational study
dc.subject.enPharmacoepidemiology
dc.subject.enPolypharmacy
dc.title.enChronic polypharmacy at all age: a population-based drug utilization study
dc.typeArticle de revueen_US
dc.identifier.doi10.1111/fcp.12727en_US
dc.subject.halSciences du Vivant [q-bio]/Santé publique et épidémiologieen_US
dc.identifier.pubmed34506043en_US
bordeaux.journalFundamental and Clinical Pharmacologyen_US
bordeaux.page405-413
bordeaux.volume36
bordeaux.hal.laboratoriesBordeaux Population Health Research Center (BPH) - UMR 1219en_US
bordeaux.issue2
bordeaux.institutionUniversité de Bordeauxen_US
bordeaux.institutionINSERMen_US
bordeaux.teamPharmacoEpi-Drugsen_US
bordeaux.teamAHEAD_BPH
bordeaux.peerReviewedouien_US
bordeaux.inpressnonen_US
hal.identifierhal-03419451
hal.version1
hal.date.transferred2021-11-08T13:49:53Z
hal.exporttrue
dc.rights.ccPas de Licence CCen_US
bordeaux.COinSctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=Fundamental%20and%20Clinical%20Pharmacology&rft.date=2022-04&rft.volume=36&rft.issue=2&rft.spage=405-413&rft.epage=405-413&rft.eissn=1472-8206%20(Electronic)%200767-3981%20(Linking)&rft.issn=1472-8206%20(Electronic)%200767-3981%20(Linking)&rft.au=GUILLOT,%20Jordan&MAUMUS-ROBERT,%20Sandy&PARIENTE,%20Antoine&BEZIN,%20Julien&rft.genre=article


Fichier(s) constituant ce document

FichiersTailleFormatVue

Il n'y a pas de fichiers associés à ce document.

Ce document figure dans la(les) collection(s) suivante(s)

Afficher la notice abrégée